Zynerba Pharmaceuticals delays data on genetic disorder drug study
Dec 21 (Reuters) – Zynerba Pharmaceuticals Inc (ZYNE.O) on Wednesday delayed the timeline for reporting key data from a trial of its cannabis-based drug to treat a rare genetic disorder, citing diffi…